Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors - Test2 - elhamkhani - TriplyDB

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

http://www.wikidata.org/entity/Q28142491

about

Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6 G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal Membrane-derived phospholipids control synaptic neurotransmission and plasticity Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.Autotaxin-lysophosphatidic acid-LPA3 signaling at the embryo-epithelial boundary controls decidualization pathways Lysophospholipid receptor nomenclature review: IUPHAR Review 8.Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis.Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MS Aiming drug discovery at lysophosphatidic acid targets.Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model.The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells The impact of bioactive lipids on cardiovascular development.LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling.Lysophosphatidic Acid signaling in the nervous system.Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.Lysophosphatidic acid induces neointima formation through PPARgamma activation.Fibroblastic reticular cell-derived lysophosphatidic acid regulates confined intranodal T-cell motility.Synthesis of photoactivatable analogues of lysophosphatidic acid and covalent labeling of plasma proteins.G(q)-dependent signalling by the lysophosphatidic acid receptor LPA(3) in gastric smooth muscle: reciprocal regulation of MYPT1 phosphorylation by Rho kinase and cAMP-independent PKA Cyclic phosphatidic acid - a unique bioactive phospholipid.Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis.Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis.Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.Stress, depression, resilience and ageing: A role for the LPA-LPA1 pathway.A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay.Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

P2860

Q24534268-5D3D01BC-5D00-4C2B-8288-C8667B900BDA Q24563311-912666E9-7707-4478-8332-FD20A082A7B8 Q24658261-8CFD7360-ECAB-47D5-A19B-A7860B9BBCE0 Q26767279-0BE4F650-8835-47B7-A89A-C9709368693F Q26828893-050F742E-7948-49F1-8775-298A3E445AA3 Q27313853-AE83E704-BC30-4C78-9475-D76CF68122E4 Q27347783-277E253C-3D90-49D1-9049-B8E7CADEAAB1 Q27349027-773D2921-B9C3-4BEA-93CE-44F9F5D8D3A5 Q28538027-C6069196-1AF6-4D07-85C9-22B3CCDA9479 Q30410634-1DADD1C8-0E8B-4F27-8F8B-4B59A04B920D Q33903608-598E9FE4-A38A-4AC3-938B-E8AD4383C083 Q34025135-2B4EF3D2-978D-4485-9A1F-FB6D259BBB8C Q34100704-9D9880B7-19BF-495C-9D8D-531D62BA5B8A Q34238735-5FC19CB4-FE2D-4C4A-8239-122A27496521 Q34339759-AA75C72A-239E-46C5-BF9C-F6583CD350C3 Q34466845-99AC2F41-3A5C-471E-8C6A-B6F3EA81276D Q34774860-62F1310E-41C9-402D-955A-D1F79EA99165 Q34776268-129EFBD6-48D1-4229-84D0-D071D71F0EE4 Q35046383-63AE73BE-749A-4833-91C6-43FCFC713D39 Q35173287-9B985B63-B640-4BD8-B5F5-CED82E09E96F Q35422290-EDD995A8-136C-429E-803E-A007D5D6F061 Q35456340-6C03DBC7-CE65-41FF-A50F-4F0447248BFD Q35598539-7D5E3233-C893-42F1-B63D-E3C721D163E2 Q36402330-604AF7DB-6242-45F5-9340-759F9846C357 Q36585912-3D282808-D132-40C3-B498-0C02206F07E4 Q36870679-10B51EA5-7E24-49B0-BF1E-5F4371B9AC7B Q36915971-A566E73D-DAA5-4BC6-9C17-7ED0D5AD5323 Q36947041-A3EB0B0A-7E5D-4A36-BB4A-A1C068D05BB1 Q37003428-F364A046-0A94-4423-80B7-CB9CE439612B Q37004375-FF3561B5-3075-4889-9C0E-B815D49AE149 Q37224388-D77F880D-C4EC-4F78-8A15-5686F0313FA9 Q37289059-D57F6DFA-4BB6-481F-99D9-89C70E98CC94 Q37375487-11C3B1B6-1663-41B2-9733-4DAE24883FD5 Q37384489-B72F46B3-FD7B-4F9B-A01D-CDA53D744B5A Q37532276-68D20D25-74A5-4691-A24B-E4FBBC7D7584 Q37700375-0B52330C-E0F4-49D8-935A-5AC6329CEFE4 Q37885347-2114A4AC-30F1-402D-94E3-30BA0A446B40 Q38658765-8331EF43-0B0F-47B8-877D-FEA80FC2EAE4 Q40966020-C12CCBE3-BE26-42E4-9D63-610678BA4F7B Q41064033-B269CFE2-1E05-49DB-8D4C-02B06D1CD997

P2860

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

http://www.wikidata.org/entity/Q28142491

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@ast

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@en

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@nl

type

label

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@ast

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@en

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@nl

prefLabel

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@ast

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@en

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@nl

P1433

Q28142491-B59713BF-D6FE-4778-877B-5A13FA4F3BF7

P1476

Q28142491-7B2BAC50-408B-47FC-8D70-92144FD57BB9

P2093

Q28142491-1C3B8ADA-8452-4B86-B990-A83E7505A8D1

Q28142491-443C5CED-CB40-4EAC-8027-F0A25C1DCE3C

Q28142491-644AD120-7137-48C9-9B6C-E70CAA77A658

Q28142491-75B2B9AB-1094-4D5A-AA1C-C6B7D3CD9F34

Q28142491-DB340244-FE1C-435B-A26F-4A76B94194D4

Q28142491-FEF1A8B1-ED86-48D6-9BA9-51CDB9B08E1F

P304

Q28142491-E3B98426-922C-4DF0-97DE-30AA54040125

P31

Q28142491-528F45F2-101B-46DB-BB1D-761B053DDA55

P407

Q28142491-C20B0AB3-D7CB-4504-BDFF-09BFD3A659DE

P433

Q28142491-2569AA64-A2DE-4663-AC0B-DFE0FC5F77FD

P478

Q28142491-00107B6F-40CE-4DF7-9FB5-A5973C8FAC08

P577

Q28142491-CAAEC7A5-92EC-4521-92CD-CAB7F35012CD

P698

Q28142491-DD9CD6ED-603E-4895-B5E9-8CB9087E3024

P1433

P1476

Lysophosphatidic acid (LPA) re ...... onship of cloned LPA receptors

@en

P2093

A Taira

http://www.w3.org/2001/XMLSchema#string

H Arai

http://www.w3.org/2001/XMLSchema#string

J Aoki

http://www.w3.org/2001/XMLSchema#string

K Bandoh

http://www.w3.org/2001/XMLSchema#string

K Inoue

http://www.w3.org/2001/XMLSchema#string

M Tsujimoto

http://www.w3.org/2001/XMLSchema#string

P304

159-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

478

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10922489

http://www.w3.org/2001/XMLSchema#string